Literature DB >> 8646743

Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies.

F H Thompson1, M A Nelson, J M Trent, X Y Guan, Y Liu, J M Yang, J Emerson, L Adair, J Wymer, C Balfour, K Massey, R Weinstein, D S Alberts, R Taetle.   

Abstract

In this study of ovarian carcinoma, we extended previous findings by performing FISH using chromosome 19 paint and microFISH probes and patient samples with and without abnormalities of chromosome 19 identified by G-banding. Karyotype interpretations of der(19) were confirmed, while additional 19 translocations were also detected by FISH with 19WCP in some cases. Similar FISH studies of ovarian carcinoma cell lines found chromosome 19 abnormalities even after extensive in vitro culture. MicroFISH probes were generated by chromosome microdissection from two cases with hsr(19) and mapped to 19q13.2 and 19q13.1-.2, respectively. FISH with these microFISH probes alone or in combination with a 19WCP probe to four patient samples and seven cell lines showed that 65% of chromosome 19 structural abnormalities contained 19q13.1-q13.2 sequences, sometimes as large hsrs. Ovarian cancer cell lines showed amplification and overexpression of the AKT2 putative oncogene, but not the ERCC-2 DNA repair gene in this chromosomal region. In addition to AKT2, amplification and overexpression of other yet-unidentified genes in the 19q13.1-q13.2 region may contribute to ovarian carcinoma pathogenesis or progression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8646743     DOI: 10.1016/0165-4608(95)00248-0

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  23 in total

1.  p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.

Authors:  Michelle K Y Siu; Hoi Yan Chan; Daniel S H Kong; Esther S Y Wong; Oscar G W Wong; Hextan Y S Ngan; Kar Fai Tam; Hongquan Zhang; Zhilun Li; Queeny K Y Chan; Sai Wah Tsao; Staffan Strömblad; Annie N Y Cheung
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-06       Impact factor: 11.205

2.  Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.

Authors:  Meng Chen; Jian Gu; George L Delclos; Ann M Killary; Zhen Fan; Michelle A T Hildebrandt; Robert M Chamberlain; H Barton Grossman; Colin P Dinney; Xifeng Wu
Journal:  Carcinogenesis       Date:  2010-06-07       Impact factor: 4.944

3.  Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1).

Authors:  M Sugimoto; T Nakamura; N Ohtani; L Hampson; I N Hampson; A Shimamoto; Y Furuichi; K Okumura; S Niwa; Y Taya; E Hara
Journal:  Genes Dev       Date:  1999-11-15       Impact factor: 11.361

4.  Optimal classes of chemotherapeutic agents sensitized by specific small-molecule inhibitors of akt in vitro and in vivo.

Authors:  Yan Shi; Xuesong Liu; Edward K Han; Ran Guan; Alexander R Shoemaker; Anatol Oleksijew; Keith W Woods; John P Fisher; Vered Klinghofer; Loren Lasko; Thomas McGonigal; Qun Li; Saul H Rosenberg; Vincent L Giranda; Yan Luo
Journal:  Neoplasia       Date:  2005-11       Impact factor: 5.715

5.  19q13 amplification is associated with high grade and stage in pancreatic cancer.

Authors:  Riina Kuuselo; Ronald Simon; Ritva Karhu; Pierre Tennstedt; Andreas H Marx; Jakob R Izbicki; Emre Yekebas; Guido Sauter; Anne Kallioniemi
Journal:  Genes Chromosomes Cancer       Date:  2010-06       Impact factor: 5.006

6.  Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells.

Authors:  Jing Hu; Eileen Friedman
Journal:  Genes Cancer       Date:  2010-08-01

7.  Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.

Authors:  Jane Bayani; Paula Marrano; Cassandra Graham; Yingye Zheng; Lin Li; Dionyssios Katsaros; Heini Lassus; Ralf Butzow; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2010-08-11       Impact factor: 6.603

Review 8.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

9.  Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.

Authors:  Jing Hu; Holly Deng; Eileen A Friedman
Journal:  Int J Cancer       Date:  2012-11-21       Impact factor: 7.396

10.  Genomic signatures predict poor outcome in undifferentiated pleomorphic sarcomas and leiomyosarcomas.

Authors:  Sara Martoreli Silveira; Rolando Andre Rios Villacis; Fabio Albuquerque Marchi; Mateus de Camargo Barros Filho; Sandra Aparecida Drigo; Cristovam Scapulatempo Neto; Ademar Lopes; Isabela Werneck da Cunha; Silvia Regina Rogatto
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.